|
| Friday, 24 November 2017, 14:07 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Nov 24, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data on its antiepileptic drugs (AED) perampanel (product name: Fycompa) and rufinamide (product name: Inovelon, U.S. product name: BANZEL) will be presented at the 71st American Epilepsy Society (AES) Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States.
As major presentations, for perampanel this includes a report on the extrapolation of data from Phase III clinical studies on adjunctive treatment to evaluate perampanel for use as monotherapy for partial seizures. Regarding rufinamide, a poster presentation will be given on long-term safety and efficacy of rufinamide for patients with Lennox-Gastaut syndrome (LGS) in a real-world setting in Japan. A total of nine poster presentations will be given at this year's AES meeting.
Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. It is available in tablet form to be taken once daily, and a new oral suspension formulation has been approved and is being marketed in the United States. A highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at postsynaptic AMPA receptors, it is approved in countries around the world as an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures, and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. Furthermore, perampanel is approved for use as monotherapy for partial-onset seizures in patients with epilepsy 12 years of age and older in the United States.
Rufinamide is believed to exert its antiepileptic effects by regulating activity of voltage-gated sodium channels in the brain involved in the overexcitement of neurons that potentially causes seizures, so as to prolong their inactive state. The agent is approved as an adjunctive therapy to other AEDs in the treatment of seizures associated with LGS in Europe and the United States. In Japan, the agent is approved as an adjunctive therapy to other AEDs in the treatment of tonic and atonic seizures associated with LGS when therapy with other AEDs is considered inadequate.
Eisai considers neurology a therapeutic area of focus, and strives to maximize the value of perampanel and rufinamide to further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
